Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study

BACKGROUND: Epilepsy occurs in up to 90 % of all individuals with tuberous sclerosis complex (TSC). In 67 % disease onset is during childhood. In ≥ 50 % seizures are refractory to currently available treatment options. The mTOR-Inhibitor Everolimus (Votubia®) was approved for the treatment of subepe...

Descripción completa

Detalles Bibliográficos
Autores principales: Samueli, Sharon, Abraham, Klaus, Dressler, Anastasia, Gröppel, Gudrun, Mühlebner-Fahrngruber, Angelika, Scholl, Theresa, Kasprian, Gregor, Laccone, Franco, Feucht, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094073/
https://www.ncbi.nlm.nih.gov/pubmed/27809914
http://dx.doi.org/10.1186/s13023-016-0530-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094073/
https://www.ncbi.nlm.nih.gov/pubmed/27809914
http://dx.doi.org/10.1186/s13023-016-0530-z

Ejemplares similares